# Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer

> **NCT02726503** · PHASE2 · COMPLETED · sponsor: **Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan** · enrollment: 39 (estimated)

## Conditions studied

- Anaplastic Thyroid Cancer

## Interventions

- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT02726503
- **Lead sponsor:** Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-04
- **Primary completion:** 2020-02-25
- **Final completion:** 2020-03-20
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2020-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02726503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02726503, "Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02726503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*